Results 101 to 110 of about 12,625 (176)

Nirmatrelvir/Ritonavir-Induced Calcium Channel Blocker Intoxication Successfully Treated by High Dose Insulin Therapy. [PDF]

Acta Cardiol Sin
Chen CY, Cia CT.
europepmc   +1 more source

Nirmatrelvir/Ritonavir Efficacy in Immunocompetent Patients with Confirmed Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2: An Updated Systematic Review and Meta-analysis. [PDF]

J Res Pharm Pract
Khani E, Afsharirad H, Yadegari AT, Zarezadeh M, Asham H, Bannazadeh-Baghi H, Entezari-Maleki T.   +6 more
europepmc   +1 more source

Nirmatrelvir/ritonavir use reduces risk for long COVID in patients with immunodeficiency. [PDF]

J Hum Immun
Gilbert KM, Aglan M, Jogdand A, Khairnar NV, Ssemaganda H, Ong MS, Farmer JR.   +6 more
europepmc   +1 more source

Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study. [PDF]

Front Cell Infect Microbiol
Zhang Y, Yang X, Sun L, Zhang R, Fan W, Lin N, Lin B.   +6 more
europepmc   +1 more source

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients.

JAMA Netw Open
Png ME, Harris V, Yu LM, Little P, Hobbs FDR, Butler CC, Petrou S, PANORAMIC Trial Collaborative Group.   +7 more
europepmc   +1 more source

Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation. [PDF]

J Am Heart Assoc
Wong CK, So BY, Leung IS, Choo A, Chiu HAC, Tam FC, Lin M, Kwok WC, Lam SC, Chan KE, Un KC, Lam TH, Chu WM, Tam AR, Hung FN, Lip GYH, Tse HF.   +16 more
europepmc   +1 more source

Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID diabetes risk among an older adult cohort: a target trial emulation study. [PDF]

BMC Med
Guo Z, Wei Y, Yang A, Wong CKH, Xiong X, Wang K, Lin G, Wang H, Hung CT, Li C, Yam CHK, Chow TY, Zhao S, Mok CKP, Hui DSC, Yeoh EK, Chong KC.   +16 more
europepmc   +1 more source

Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in COVID-19 Patients with Type-2 Diabetes

Background:Emerging evidence suggested the significantly increased risk of all-cause mortality in COVID-19patients with type-2 diabetes. However, direct comparison on the effectiveness of molnupiravir andnirmatrelvir-ritonavir among COVID-19 patients ...
Lai, FranciscoTT, Wong, Ian CK, Li, Xue, Wan, Eric YF, Chan, Esther Wai Yin, Wong, Zoey CT, Chui, Celine SL, Yan, Vincent KC   +7 more
core  

Pharmacist follow-up of patients prescribed nirmatrelvir/ritonavir: a single-center retrospective analysis. [PDF]

J Pharm Health Care Sci
Shigeno A, Ohashi Y, Masui R, Kiryu A, Nagashima K, Ohashi H, Seto K, Masuda J, Teruya K, Ujiie M, Ohmagari N, Nishimura T.   +11 more
europepmc   +1 more source

Association of Nirmatrelvir-ritonavir with intubation or mortality risks in severe COVID-19 patients: a comparative study. [PDF]

BMC Infect Dis
Luo W, Li KY, Zhu W, Dai C, Lin J, Lu F, Chen Q, Wang W, Zhuang Q, Lin Y.   +9 more
europepmc   +1 more source